iah0968
HER2 Gene Mutation
SUNHO（China）BioPharmaceutical CO., Ltd.Phase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the HER2 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 2/3 | B |
Docetaxel Intergroupe Francophone de Cancerologie Thoracique | Phase 2 | B |
Eloxatin SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 2/3 | B |
Neratinib Maleate Korea University Guro Hospital | Phase 2 | B |
Herzuma Korea University Guro Hospital | Phase 2 | B |
View all 15 →
Same molecule, other indications
iah0968 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →